Deals
Amgen Is Open to Bigger Deals While Staying Disciplined
- `More energetic about being out there,' CFO says in interview
- Amgen considering bigger targets after focusing on smaller M&A
This article is for subscribers only.
After sitting out for most of the biotech acquisition frenzy of 2015, Amgen Inc. is ready to do a deal.
In the past year, the drugmaker has introduced six products, digested its last major acquisition -- the $10 billion purchase of cancer drugmaker Onyx in 2013 -- and undertaken a companywide restructuring. Time is ripe for bigger targets again, and the challenge is to be patient, says Chief Financial Officer David Meline.